Attorneys eyeing lawsuits over Zantac may be divided on the significance of the U.S. Food and Drug Administration’s decision calling on drugmakers to pull the heartburn medication from the market, but all agree the move highlights what appears to be a growing unease over the safety of the medication.

On Wednesday, the regulatory body announced it was requesting manufacturers to withdraw all prescription and over-the-counter Zantac from the market over concerns that a potentially carcinogenic molecule in the drug may build up over time if the medication is stored above room temperature. According to a press release issued Wednesday, the move is part of an ongoing investigation into the molecule N-Nitrosodimethylamine, or NDMA, which is a component of the drug.